RAZADYNE 24 MG

Barr Confirms Patent Challenge Of Razadyne(R) ER Capsules email to a friend printer friendly view / write opinions rate articleBarr Pharmaceuticals, Inc. (NYSE: BRL) today confirmed that Janssen Pharmaceutica N.V., Janssen, L.P., Ortho-McNeil Neurologics, Inc. and Synaptech, Inc. ("Plaintiff") filed suit against it and its subsidiary, Barr Laboratories, Inc., relating to the patent protecting Razadyne(R) ER (Galantamine Hydrobromide Extended-Release Capsules), 8 mg, 16 mg and 24 mg. The Company indicated it believes it is the first to file an Abbreviated New Drug Application (ANDA) with the U.S. Food & Drug Administration (FDA) for the product. Except for the historical information contained herein, the statements made in this press release constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements can be identified by their use of words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates" and other words of similar meaning. Because such statements inherently involve risks and uncertainties that cannot be predicted or quantified, actual results may differ materially from those expressed or implied by such forward-looking statements depending upon a number of factors affecting the Company's business.